Fig. 2From: Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathwaysTime course of creatine kinase, calibrated anti-factor Xa activity, and apixaban concentrations measured by ultra-performance liquid chromatography-tandem mass spectrometryBack to article page